您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > MLN3126
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MLN3126
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MLN3126图片
CAS NO:628300-71-0
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
200mg电议

产品介绍
MLN3126 是一种具有口服活性的强效CCR9拮抗剂。 MLN3126 抑制 CCL25 诱导的钙动员 (calcium mobilization) 和小鼠初级胸腺细胞趋化 (chemotaxis),抑制钙内流的IC50为 6.3 nM。
生物活性

MLN3126 is an orally active and potentCCR9antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht anIC50value of 6.3 nM forcalcium influx[1].

体外研究
(In Vitro)

MLN3126 inhibits CCL25-induced calcium mobilization with an IC50value of 6.3 nM in CCR9 expressing cells[1].
MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC50of 14.2 nM[1].

Cell Invasion Assay[1]

Cell Line:Mouse thymocytes
Concentration:0.01, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:90 min
Result:Inhibited CCL25-induced chemotaxis of mouse thymocytes.
体内研究
(In Vivo)

MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells[1].
MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD)[1].

Animal Model:Activated T cell transferred colitis mouse model[1]
Dosage:0.05, 0.25 and 1% (w/w) (around 4 g/day)
Administration:Oral gavage; 21 days
Result:Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis.
Clinical Trial
分子量

446.90

性状

Solid

Formula

C21H19ClN2O5S

CAS 号

628300-71-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 25 mg/mL(55.94 mM;ultrasonic and warming and heat to 60℃)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.2376 mL11.1882 mL22.3764 mL
5 mM0.4475 mL2.2376 mL4.4753 mL
10 mM0.2238 mL1.1188 mL2.2376 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。